A daily weight loss pill from Novo Nordisk was shown to lower body weight by up to 13% after three months in a Phase 1 ...

Novo Nordisk (NVO) stock rises after full results from an early-stage trial of weight-loss pill amycretin. Read more here.

"EASD 2024: Novo Nordisk’s Saxenda shows weight loss in children" was originally created and published by Pharmaceutical ...

A new study found that women using the weight loss drug tirzepatide (Mounjaro) lost more weight than men, but experienced ...

(Reuters) - European shares slipped on Friday after a rally in the previous session spurred by U.S. Federal Reserve's ...

Danish pharma giant Novo Nordisk has reported promising data on its new weight loss pill, which has been shown to lower body ...

All major European markets were trading lower, except Spain’s that edged up 0.1% ... European Medicines Agency backed the use ...

Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to ...

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage ...

Martin Lange, executive vice president and head of development at Novo Nordisk, said in a statement that amycretin works in a similar way to semaglutide, the drug in Wegovy and Ozempic.

Researchers in France have developed a once-a-month hydrogel-based delivery system for semaglutide, significantly simplifying ...

A new study found that women using the weight loss drug tirzepatide, also known by its brand name Mounjaro, experienced greater weight loss than men. Still, all doses of the medication were shown ...